GeNeuro SA (GEM.F)
- Previous Close
1.3250 - Open
1.3250 - Bid 1.3350 x 40000
- Ask 1.5400 x 40000
- Day's Range
1.3250 - 1.3250 - 52 Week Range
0.8540 - 1.9750 - Volume
100 - Avg. Volume
31 - Market Cap (intraday)
42.323M - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family; treats type 1 diabetes; and treats chronic inflammatory demyelinating polyneuropathy. It also developing GNK301. In addition, It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
www.geneuro.comRecent News: GEM.F
Performance Overview: GEM.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GEM.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GEM.F
Valuation Measures
Market Cap
42.32M
Enterprise Value
47.71M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.84
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.39M
Diluted EPS (ttm)
-0.5400
Balance Sheet and Cash Flow
Total Cash (mrq)
7.4M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Company Insights: GEM.F
GEM.F does not have Company Insights